INSIGHTS ON DRUG DEVELOPMENT

• Immuno-Oncology Biomarker Measurement With High Sensitivity And Speed

  Explore results demonstrating the successful use of innovative ELISA assays to detect three key biomarkers: Programmed Death Ligand 1 (PD-L1), Interleukin-8 (IL-8), and Interferon Gamma (IFN-γ).

• Safety, Containment, And Analysis Of Highly Potent Compounds

  Explore a comprehensive overview of the challenges, requirements, and best practices for safely working with highly potent compounds in drug development and manufacturing.

• Nose To Brain (N2B) Drug Delivery – Benefits And Challenges

  Delve into the growing interest in drug delivery methods that target the brain and central nervous system via absorption into the bloodstream, specifically focusing on crossing the blood-brain barrier (BBB).

• 5 Key Considerations For Companies Outsourcing Process Development

  Venture capital in biotech remains strong post-pandemic, especially in cell and gene therapies. Discover five key factors to help companies choose between in-house and outsourced process development strategies.

• Targeted Modalities Set Elevated Standards For Precision

  4/7/2026

  Explore how targeted modalities like ADCs and TPDs are transforming precision medicine, unlocking new treatment opportunities, and overcoming development challenges to improve patient outcomes.

• Cost Modeling Analysis Of AAV And LV Manufacturing

  3/31/2026

  Manufacturing scale plays a critical role in viral vector economics. Compare AAV and LV production scenarios to gain insight into how intermediate-scale strategies can reduce cost and risk.

• How To Accelerate And Enhance ADC Therapies

  6/24/2024

  Learn how payloads and advanced payload intermediates can expedite drug development and elevate ADC therapies, and explore ADC payloads, payload intermediates, and solubility-enhancing technology.

• NGS In GMP Manufacturing: Reducing Risk, Increasing Return

  1/29/2026

  Global regulators now recognize NGS as a rigorous, GMP‑ready tool for viral safety, driving a shift toward scalable quality strategies. Learn why NGS is becoming central to modern manufacturing.

• Can Collaboration Close Biopharma's Talent Gap For Good?

  3/17/2026

  Biopharma innovation is accelerating, but workforce shortages threaten progress. See how strengthening collaboration is essential to developing the skills needed for emerging therapies.